What type of study is this?

September 5, 2025Open Access

Figure S5 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Key Points

Body weight does not change significantly with niraparib treatment, suggesting a stable condition during the study.
In MDA-MB-436 models, niraparib at 15 mg/kg was administered daily for 28 days, with no adverse effects on weight.
DLD-1 BRCA2 null models received niraparib at 30 and 60 mg/kg daily for 20 days without impacting body weight.
This observation highlights the potential safety of niraparib in treating BRCA-mutated tumors despite POLB's involvement.

Abstract

Supplementary Figure S5. Body weight of the animals is not impacted by the treatment with niraparib – related to Figure 6. A) Effect on body weights of animals containing MDA-MB-436 sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 15 mpk once daily for 28 days. Data is represented as % change in body weights until day 28. B) Effect on body weights of animals containing DLD-1 BRCA2 null sgIntron or sgPOLB xenografts treated with vehicle and niraparib at 30 mpk (left) and 60 mpk (right) once daily for 20 days. Data is represented as % change in body weights until day 20.

Read Full Paperexternally

问 AI

Bookmark

View Full Paper